IK
IKT.US Inhibikase Therapeutics Inc
- Market cap
- USD 213M
- P/E
- -
- P/B
- 1.13x
- ROE
- -39.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IKT.US undervalued?
Graham numberThe Graham number of Inhibikase Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Inhibikase Therapeutics Inc fundamental analysis
No fundamental analysis for Inhibikase Therapeutics Inc yet.
Inhibikase Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PA…
Full company profileInhibikase Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Inhibikase Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 967K | 2.06M | 4.04M | 1.12M | 698K | 3.10M | 123K | 261K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 121K | 305K | 4.04M | -1.43M | 698K | 3.10M | 117K | -13.4M | -26.3K | -60.5K | - |
| Operating Income | -613K | -405K | -2.12M | -5.70M | -2.82M | -14.8M | -18.1M | -20.1M | -28.6M | -52.0M | -82.0M |
| EBITDA | - | - | -2.12M | -5.70M | -2.82M | -14.8M | -18.0M | -18.9M | -27.5M | -53.3M | -75.3M |
| Net Income | -629K | -436K | -2.15M | -5.75M | -2.88M | -14.8M | -18.1M | -19.0M | -27.5M | -48.3M | -75.3M |
| EPS | -0.48 | -0.25 | -1.61 | -3.34 | -1.72 | -4.88 | -4.30 | -3.57 | -1.16 | -0.49 | -0.38 |
| Balance Sheet | |||||||||||
| Total Assets | 163K | 285K | 2.85M | 38.3K | 14.8M | 42.5M | 24.9M | 14.5M | 98.6M | 181M | 202M |
| Total Liabilities | 1.51M | 1.73M | 3.62M | 4.53M | 5.00M | 4.05M | 3.90M | 3.53M | 3.73M | 8.30M | 13.0M |
| Shareholders' Equity | -1.35M | -1.44M | -778K | -4.49M | 9.78M | 38.4M | 21.0M | 11.0M | 94.9M | 173M | 189M |
| Cash & Short-term Investments | 12.0K | 16.7K | 380K | 18.5K | 14.0M | 40.8M | 23.1M | 13.3M | 97.5M | 179M | 193M |
| Total Debt | 329K | 460K | 234K | 374K | 319K | 249K | 351K | 622K | 111K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -29.6K | -126K | 715K | -338K | -1.13M | -14.3M | -17.4M | -18.1M | -19.1M | -27.8M | -55.8M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 243K | 14.2K | 0.00 | 13.4K | 0.00 |
| Free Cash Flow | -29.6K | -126K | 715K | -338K | -1.13M | -14.3M | -17.6M | -18.1M | -19.1M | -27.8M | -55.8M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -29.4% | -38.5% | -85.8% | -173.3% | -29.0% | -27.9% | -39.9% |
| ROA | -385.9% | -152.9% | -75.6% | -15,025.4% | -19.5% | -34.9% | -72.4% | -131.2% | -27.9% | -26.6% | -37.3% |
| Net Profit Margin | -65.0% | -21.2% | -53.3% | -511.9% | -411.9% | -477.5% | -14,625.9% | -7,304.8% | - | - | - |
| Debt to Equity | - | - | - | - | 0.03x | 0.01x | 0.02x | 0.06x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Inhibikase Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 77.7K | 0.03 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:6 on Jun 30, 2023.
Who owns Inhibikase Therapeutics Inc
- Insiders 6.50%
- Institutions 91.61%
- Public & others 1.89%
- Shares outstanding 140M
- Free float 108M
Top funds holding IKT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.76M | 2.68% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.38M | 2.41% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.33M | 0.95% | +0.84% | Aug 2026 |
| iShares Russell 2000 Value ETF | 1.30M | 0.93% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 840K | 0.60% | +20.69% | Sep 2026 |
| Fidelity Extended Market Index | 459K | 0.33% | +7.39% | Sep 2026 |
| iShares Micro-Cap ETF | 437K | 0.31% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 351K | 0.25% | +19.36% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 258K | 0.18% | +9.09% | Sep 2026 |
| CREF Total Global Stock Account R3 | 182K | 0.13% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 182K | 0.13% | +328.54% | Oct 2026 |
| Nuveen Small Cap Blend Idx R6 | 182K | 0.13% | +12.57% | Sep 2026 |
| Fidelity Small Cap Value Index | 177K | 0.13% | +0.45% | Aug 2026 |
| ALPS Medical Breakthroughs ETF | 170K | 0.12% | 0.00% | Oct 2026 |
| JPMorgan Small Cap Value I | 164K | 0.12% | -2.06% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 163K | 0.12% | +127.20% | Aug 2026 |
| Fidelity Total Market Index | 148K | 0.11% | -0.05% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 137K | 0.10% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 Value ETF | 133K | 0.10% | +18.43% | Sep 2026 |
| Fidelity Series Total Market Index | 129K | 0.09% | 0.00% | Sep 2026 |
Top institutions holding IKT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sands Capital Ventures, LLC | 13.0M | 9.28% | 0.00% | Jun 2026 |
| Soleus Capital Management, L.P. | 10.9M | 7.75% | 0.00% | Jun 2026 |
| Trails Edge Capital Partners, LP | 9.05M | 6.45% | +12.34% | Jun 2026 |
| Fairmount Funds Management LLC | 8.63M | 6.15% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.77M | 5.54% | +23.24% | Jun 2026 |
| Kalehua Capital Management LLC | 7.64M | 5.45% | +17.70% | Jun 2026 |
| ADAR1 Capital Management LLC | 7.39M | 5.27% | +11.82% | Jun 2026 |
| Blackstone Inc | 5.94M | 4.23% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 5.85M | 4.17% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 5.40M | 3.85% | +100.00% | Jun 2026 |
| COMMODORE CAPITAL LP | 5.40M | 3.85% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.94M | 3.52% | +10.89% | Jun 2026 |
| Millennium Management LLC | 4.03M | 2.87% | +37.57% | Jun 2026 |
| Saturn V Capital Management LLC | 3.87M | 2.76% | +0.15% | Jun 2026 |
| Spruce Street Capital LP | 3.58M | 2.55% | 0.00% | Jun 2026 |
| Squadron Capital Management LLC | 3.00M | 2.14% | -14.29% | Jun 2026 |
| Geode Capital Management, LLC | 2.61M | 1.86% | +20.13% | Jun 2026 |
| State Street Corp | 1.91M | 1.36% | +13.24% | Jun 2026 |
| SummitTX Capital, L.P | 1.78M | 1.27% | +16.77% | Jun 2026 |
| Integral Health Asset Management, LLC | 1.35M | 0.96% | 0.00% | Jun 2026 |
Inhibikase Therapeutics Inc company profile
- Company name
- Inhibikase Therapeutics Inc
- Ticker
- IKT.US
- Exchange
- USA Stocks
- Listed since
- Dec 23, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
- Fiscal year end
- December
- Address
- 1000 N. West Street, Wilmington, DE, United States, 19801
- Phone
- 302 295 3800
- Website
- inhibikase.com
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Inhibikase Therapeutics Inc management
7- Mr. Mark T. IwickiCEO & Director · born 1966
- Dr. Christopher H. Cabell FACC, M.D.President, Head of Research & Development and Chief Medical Officer · born 1969
- Mr. David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A.Chief Financial Officer · born 1970
- Dr. John Adams Ph.D.Chief Scientific Officer
- Mr. Jeffrey J. KagyChief Human Resources Officer
- Mr. Chadwick J. Orevillo MPHExecutive VP & Head of Development Operations
- Mr. Timothy J. PigotChief Commercial & Strategy Officer · born 1971